Metformin reduces Afib after ablation
Obese or overweight non-diabetic adults with atrial fibrillation (Afib) who take the diabetes medication metformin after a catheter ablation are more likely to remain free of AFib for… read more.
Obese or overweight non-diabetic adults with atrial fibrillation (Afib) who take the diabetes medication metformin after a catheter ablation are more likely to remain free of AFib for… read more.
At ObesityWeek taking place in Atlanta, US, Novo Nordisk presented new findings from the STEP UP phase IIIb trial. It showed that, in addition to losing an average… read more.
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that… read more.
A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight… read more.
MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as… read more.
The prevalence of obesity in the United States could rise sharply under a new definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission. Researchers… read more.
Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s. The test estimates an individual’s… read more.
More than half of all adults without diabetes who began taking semaglutide discontinued treatment within a year, according to new research on Danish patients. The population-wide study was… read more.
Soaring demand for GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, is driving a surge in the online sale of illegal medicines. The European Medicines Agency (EMA)… read more.
The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study being presented at… read more.
Researchers report that patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) have achieved a 78% reduced risk of death and a 44% reduced risk of major… read more.
Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers. A new study has… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.